Document Detail

Aberrant p15 promoter methylation in adult and childhood acute leukemias of nearly all morphologic subtypes: potential prognostic implications.
MedLine Citation:
PMID:  10706859     Owner:  NLM     Status:  MEDLINE    
We prospectively analyzed p15 and p16 promoter methylation patterns using methylation-specific polymerase chain reaction (PCR) in patients with adult and childhood acute leukemias and studied the association of methylation patterns with chromosomal abnormalities and prognostic variables. In nearly all French-American-British leukemia subtypes, we found p15 methylation in bone marrow or peripheral blood cells from 58% (46/79) of patients with acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), or acute biphenotypic leukemia (ABL). An identical alteration was detected in blood plasma from 11 of 12 of these patients (92%). We also demonstrated for the first time concomitant p16 and p15 methylation in 22% (8/37) of adults with AML or ALL, exclusively in those with M2, M4, or L2 subtypes. According to cytogenetic data from 35 patients with ALL, AML, or ABL, 82% (14/17) of those with unmethylated p15 alleles had normal karyotypes or hyperdiploidies associated with a favorable prognosis. Conversely, 44% (8/18) of patients with p15 methylation had chromosomal translocations, inversions, or deletions, suggesting an interplay of these abnormalities with p15 methylation. As a prognostic marker for disease monitoring, p15 methylation appears to be more widely applicable than BCR-ABL, AF4-MLL, and AML1-ETO transcripts, which were detectable in only 8% (4/48) of patients by reverse transcriptase-PCR. Thirty-nine of 43 blood samples (91%) sequentially collected from 12 patients with AML, ALL, or ABL showed p15 methylation status in excellent concordance with morphologic disease stage. Early detection of p15 methylation at apparent remission or its acquisition during follow-up may prove valuable for predicting relapse. Overall survival of patients with p15 methylation was notably shortened among 38 adults with AML and 12 adults with ALL. Aberrant p15 methylation may have important prognostic implications for clinical monitoring and risk assessment. (Blood. 2000;95:1942-1949)
I H Wong; M H Ng; D P Huang; J C Lee
Related Documents :
2226739 - Abnormal chromatin clumping in leucocytes: a clue to a new subtype of myelodysplastic s...
6897059 - Lymphoblastic lymphoma: cytogenetic, pathologic, and immunologic studies.
6192899 - Red cell aplasia in myelofibrosis with myeloid metaplasia. a distinct functional and cl...
8374529 - The relationship between the type of bcr-abl hybrid messenger rna and thrombopoiesis in...
10674899 - Aberrant immunophenotypes detected by flow cytometry in acute lymphoblastic leukemia.
2927179 - Cytogenetic heterogeneity in erythroleukemia defined as m6 by the french-american-briti...
9818899 - Paraneoplastic encephalomyelitis and seminoma: importance of testicular ultrasonography.
707889 - Excessive polycythemia of high altitude: role of ventilatory drive and lung disease.
11806769 - The carvedilol prospective randomized cumulative survival (copernicus) trial.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Blood     Volume:  95     ISSN:  0006-4971     ISO Abbreviation:  Blood     Publication Date:  2000 Mar 
Date Detail:
Created Date:  2000-04-07     Completed Date:  2000-04-07     Revised Date:  2008-11-21    
Medline Journal Info:
Nlm Unique ID:  7603509     Medline TA:  Blood     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  1942-9     Citation Subset:  AIM; IM    
Department of Anatomical and Cellular Pathology, Prince of Wales Hospital, Chinese University of Hong Kong, Hong Kong.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Acute Disease
Age Factors
Aged, 80 and over
Blotting, Southern
Cell Cycle Proteins*
Child, Preschool
Cyclin-Dependent Kinase Inhibitor p15
Cyclin-Dependent Kinase Inhibitor p16 / genetics
Leukemia / blood,  genetics*,  mortality
Leukemia, Myelomonocytic, Acute / blood,  genetics*,  mortality
Middle Aged
Precursor Cell Lymphoblastic Leukemia-Lymphoma / blood,  genetics*,  mortality
Promoter Regions, Genetic*
Reverse Transcriptase Polymerase Chain Reaction
Risk Factors
Time Factors
Transcription Factors / genetics*
Tumor Suppressor Proteins*
Reg. No./Substance:
0/CDKN2B protein, human; 0/Cell Cycle Proteins; 0/Cyclin-Dependent Kinase Inhibitor p15; 0/Cyclin-Dependent Kinase Inhibitor p16; 0/Transcription Factors; 0/Tumor Suppressor Proteins
Comment In:
Blood. 2000 Sep 1;96(5):2002   [PMID:  11041632 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Genetic analysis, phenotypic diagnosis, and risk of venous thrombosis in families with inherited def...
Next Document:  Non-MALT marginal zone B-cell lymphomas: a description of clinical presentation and outcome in 124 p...